Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

Gilead Recalls Two Lots of Remdesivir Due to Glass Contamination


On December 3rd, the FDA announced that Gilead voluntarily recalled thousands of remdesivir vials due to the presence of glass particulates.

After a customer complaint, an internal investigation confirmed glass particles in two lots.

The contaminated lots were distributed to wholesalers between 10/25/21 and 11/2/21.

Glass contamination presents potentially catastrophic dangers to patients.

As the FDA stated:

Risk Statement: The administration of an injectable product that contains glass particulates may result in local irritation or swelling in response to the foreign material. If the glass particulate reaches the blood vessels it can travel to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death. To date, Gilead Sciences Inc. has not received any reports of adverse events related to this recall.

In total, the recall included 55,000 vials of the antiviral drug.

That’s enough to treat 11,000 hospitalized patients.

But honestly, it’s best that Gilead dump every single vial of remdesivir in the trash.

As Dr. Bryan Ardis explained, remdesivir is toxic and has led to countless deaths of hospitalized COVID-19 patients.

Remdesivir is the only FDA-approved antiviral drug to treat COVID-19, but it’s responsible for catastrophic side effects like multi-organ dysfunction syndrome and kidney failure.

So, Gilead can do us a favor by throwing more vials of remdesivir in the dumpster.

And the FDA can do us a bigger favor by approving hydroxychloroquine and ivermectin.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

We Love Trump
Thanks for sharing!